Trial Profile
Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 12 Oct 2022
Price :
$35
*
At a glance
- Drugs GSK 3390107A (Primary) ; RVSV-S-GP/VP40 vaccine (Primary)
- Indications Ebola virus infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Acronyms PREVAIL
- 05 Oct 2022 Results of post-hoc pooled analysis of 3 studies(PREVAIL:NCT02344407; FLW: PACTR201503001057193; STRIVE:NCT02378753) published in the Vaccine
- 17 Mar 2021 Status changed from active, no longer recruiting to completed.
- 25 Oct 2020 Results of post-hoc pooled analysis of 3 studies (Guinea (FLW), Sierra Leone (STRIVE), and Liberia (PREVAIL)), presented at the IDWeek 2020.